pharmaphorum March 26, 2025
Character Biosciences has raised $93m in an oversubscribed Series B round to speed the clinical development of a pipeline of drugs for progressive vision disorders, starting with age-related macular degeneration (AMD).
The New Jersey, US-based biotech is focusing its efforts on two lead candidates – codenamed CTX203 and CTX114 – which it says target key drivers of retinal cell death and vision loss in AMD, a sight-robbing disease that affects millions of people worldwide.
CTX114 is a complement inhibitor designed to slow the progression of geographic atrophy in advanced dry AMD, while Character CTX203 is a lipid regulator designed to prevent progression to advanced AMD. The two candidates are still in early-stage development and are due to start clinical testing...
Today's Sponsors
Today's Sponsor